PExA (PEXA) Q2 2026 earnings summary

Executive summary

• Revenue for Q2 2026 was 82,800 SEK, down from 312,582 SEK in Q2 2025; H1 2026 revenue was 1,188,559 SEK, up from 312,581 SEK year-over-year.

• Net loss after financial items improved to -1,246,669 SEK in Q2 2026 from -2,315,399 SEK in Q2 2025; H1 2026 net loss was -2,199,311 SEK, an improvement from -4,563,974 SEK year-over-year.

• Major commercial milestone: signed an 18-month, 7.5 MSEK contract with a top-10 global pharma company for 10 PEXA 2.1 systems for an international IPF clinical study.

• Strengthened financial position post-period with over 26 MSEK raised through oversubscribed rights and directed share issues.

Financial highlights

• Q2 2026 net sales: 82,800 SEK (Q2 2025: 312,582 SEK); H1 2026: 1,188,559 SEK (H1 2025: 312,581 SEK).

• Q2 2026 net loss: -1,246,669 SEK (Q2 2025: -2,315,399 SEK); H1 2026 net loss: -2,199,311 SEK (H1 2025: -4,563,974 SEK).

• Cash and cash equivalents at June 30, 2026: 796,326 SEK (June 30, 2025: 1,683,318 SEK).

• Equity ratio at period end: 53.0% (67.1%).

• Cash flow from operations Q2 2026: -1,924,402 SEK; total cash flow Q2 2026: -3,021,396 SEK.

Outlook and guidance

• Contract with global pharma provides recurring revenue and increased predictability for coming quarters.

• Strengthened capital base enables execution of larger customer projects and continued platform development.

• Ongoing expansion into biomarker discovery, PK/PD, and diagnostics with a focus on lung disease and early detection.